Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy
Objective To investigate the serum total antibody (immunoglobulin M and immunoglobulin G) titre against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain following BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccinat...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2022/07/01, Vol.61(13), pp.1953-1958 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1958 |
|---|---|
| container_issue | 13 |
| container_start_page | 1953 |
| container_title | Internal Medicine |
| container_volume | 61 |
| creator | Sugihara, Koichi Wakiya, Risa Shimada, Hiromi Kameda, Tomohiro Nakashima, Shusaku Kato, Mikiya Miyagi, Taichi Mizusaki, Mao Mino, Rina Nomura, Yumi Inoo, Masayuki Kadowaki, Norimitsu Dobashi, Hiroaki |
| description | Objective To investigate the serum total antibody (immunoglobulin M and immunoglobulin G) titre against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain following BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination in Japanese rheumatic disease patients undergoing immunosuppressive therapy. Methods The serum antibody titre against SARS-CoV-2 spike protein was analysed in 123 outpatients with rheumatic diseases at Kagawa University Hospital and 43 healthy volunteers who had received 2 doses of the BNT162b2 mRNA vaccine with at least 14 days elapsing since the second dose. Results The antibody titre in rheumatic disease patients was significantly lower than that in healthy subjects (p |
| doi_str_mv | 10.2169/internalmedicine.9223-21 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9334253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2683245658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c667t-80cbd89de53a0f5b581efec28a7eecb80e597b7005d75314b44d31ebf880e0943</originalsourceid><addsrcrecordid>eNplkVuP0zAQhS0EYsvCX0CWeOEliy9x4rwgLV0ulVZbVJV9tRxnkrhKnGInlSr-PI5aKlhexrLmm3PGPghhSm4YzYoP1o3gne56qKyxDm4KxnjC6DO0oDwtkpxx8RwtSEFlwmK5Qq9C2BHCZV6wl-iKizTLaCYX6Neq7yc3NOCi0HjEutHWhRGPLeBPD1uasZLhfvNwi5frx9VdQgv8qM3sia3DmxamXo_W4DsbQAfA3-MN3BjwBgzYg3UNPjmEab_3EII9AN624PX--Bq9qHUX4M35vEY_vnzeLr8l9-uvq-XtfWKyLB8TSUxZyaICwTWpRSkkhRoMkzoHMKUkIIq8zAkRVS44Tcs0rTiFspaxRYqUX6OPJ939VMYfM3E_rzu197bX_qgGbdW_HWdb1QwHVXCeMsGjwPuzgB9-ThBG1dtgoOu0g2EKimVCUMJEmkf03RN0N0xzVDMlOUtFJmSk5IkyfgjBQ31ZhhI1J6yeJqzmhGMrjr79-zGXwT-RRmB9AnZh1A1cAO1jTh38r5xRRflczxYX0rTaK3D8N3Sfxes</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2683245658</pqid></control><display><type>article</type><title>Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy</title><source>PubMed Central</source><source>J-STAGE</source><source>PubMed Central Open Access</source><creator>Sugihara, Koichi ; Wakiya, Risa ; Shimada, Hiromi ; Kameda, Tomohiro ; Nakashima, Shusaku ; Kato, Mikiya ; Miyagi, Taichi ; Mizusaki, Mao ; Mino, Rina ; Nomura, Yumi ; Inoo, Masayuki ; Kadowaki, Norimitsu ; Dobashi, Hiroaki</creator><creatorcontrib>Sugihara, Koichi ; Wakiya, Risa ; Shimada, Hiromi ; Kameda, Tomohiro ; Nakashima, Shusaku ; Kato, Mikiya ; Miyagi, Taichi ; Mizusaki, Mao ; Mino, Rina ; Nomura, Yumi ; Inoo, Masayuki ; Kadowaki, Norimitsu ; Dobashi, Hiroaki</creatorcontrib><description>Objective To investigate the serum total antibody (immunoglobulin M and immunoglobulin G) titre against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain following BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination in Japanese rheumatic disease patients undergoing immunosuppressive therapy. Methods The serum antibody titre against SARS-CoV-2 spike protein was analysed in 123 outpatients with rheumatic diseases at Kagawa University Hospital and 43 healthy volunteers who had received 2 doses of the BNT162b2 mRNA vaccine with at least 14 days elapsing since the second dose. Results The antibody titre in rheumatic disease patients was significantly lower than that in healthy subjects (p<0.0001). The antibody titres of the 41 patients who received biologics or Janus kinase inhibitors and the 47 patients who received conventional immunosuppressive agents were significantly lower than those of the 35 patients who did not receive immunosuppressive agents (p<0.0001 and p<0.0001, respectively). In addition, the mean antibody titre of the 43 patients on methotrexate was significantly lower than that of the 80 patients not on methotrexate (p=0.0017). Conclusion Immunogenicity to the BNT162b2 mRNA COVID-19 vaccine in rheumatic disease patients was found to be reduced under immunosuppressive treatment. In particular, methotrexate seems to be associated with a decreased antibody response.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.9223-21</identifier><identifier>PMID: 35466168</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Antibodies ; Antibody response ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Immunogenicity ; Immunoglobulin G ; Immunoglobulin M ; Immunoglobulins ; immunosuppression ; Immunosuppressive agents ; Internal medicine ; Janus kinase ; Methotrexate ; mRNA ; mRNA vaccine ; Original ; Patients ; rheumatic disease ; Rheumatic diseases ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Vaccination ; Vaccines</subject><ispartof>Internal Medicine, 2022/07/01, Vol.61(13), pp.1953-1958</ispartof><rights>2022 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2022</rights><rights>Copyright © 2022 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c667t-80cbd89de53a0f5b581efec28a7eecb80e597b7005d75314b44d31ebf880e0943</citedby><cites>FETCH-LOGICAL-c667t-80cbd89de53a0f5b581efec28a7eecb80e597b7005d75314b44d31ebf880e0943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334253/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334253/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35466168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sugihara, Koichi</creatorcontrib><creatorcontrib>Wakiya, Risa</creatorcontrib><creatorcontrib>Shimada, Hiromi</creatorcontrib><creatorcontrib>Kameda, Tomohiro</creatorcontrib><creatorcontrib>Nakashima, Shusaku</creatorcontrib><creatorcontrib>Kato, Mikiya</creatorcontrib><creatorcontrib>Miyagi, Taichi</creatorcontrib><creatorcontrib>Mizusaki, Mao</creatorcontrib><creatorcontrib>Mino, Rina</creatorcontrib><creatorcontrib>Nomura, Yumi</creatorcontrib><creatorcontrib>Inoo, Masayuki</creatorcontrib><creatorcontrib>Kadowaki, Norimitsu</creatorcontrib><creatorcontrib>Dobashi, Hiroaki</creatorcontrib><title>Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Objective To investigate the serum total antibody (immunoglobulin M and immunoglobulin G) titre against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain following BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination in Japanese rheumatic disease patients undergoing immunosuppressive therapy. Methods The serum antibody titre against SARS-CoV-2 spike protein was analysed in 123 outpatients with rheumatic diseases at Kagawa University Hospital and 43 healthy volunteers who had received 2 doses of the BNT162b2 mRNA vaccine with at least 14 days elapsing since the second dose. Results The antibody titre in rheumatic disease patients was significantly lower than that in healthy subjects (p<0.0001). The antibody titres of the 41 patients who received biologics or Janus kinase inhibitors and the 47 patients who received conventional immunosuppressive agents were significantly lower than those of the 35 patients who did not receive immunosuppressive agents (p<0.0001 and p<0.0001, respectively). In addition, the mean antibody titre of the 43 patients on methotrexate was significantly lower than that of the 80 patients not on methotrexate (p=0.0017). Conclusion Immunogenicity to the BNT162b2 mRNA COVID-19 vaccine in rheumatic disease patients was found to be reduced under immunosuppressive treatment. In particular, methotrexate seems to be associated with a decreased antibody response.</description><subject>Antibodies</subject><subject>Antibody response</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Immunogenicity</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Immunoglobulins</subject><subject>immunosuppression</subject><subject>Immunosuppressive agents</subject><subject>Internal medicine</subject><subject>Janus kinase</subject><subject>Methotrexate</subject><subject>mRNA</subject><subject>mRNA vaccine</subject><subject>Original</subject><subject>Patients</subject><subject>rheumatic disease</subject><subject>Rheumatic diseases</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNplkVuP0zAQhS0EYsvCX0CWeOEliy9x4rwgLV0ulVZbVJV9tRxnkrhKnGInlSr-PI5aKlhexrLmm3PGPghhSm4YzYoP1o3gne56qKyxDm4KxnjC6DO0oDwtkpxx8RwtSEFlwmK5Qq9C2BHCZV6wl-iKizTLaCYX6Neq7yc3NOCi0HjEutHWhRGPLeBPD1uasZLhfvNwi5frx9VdQgv8qM3sia3DmxamXo_W4DsbQAfA3-MN3BjwBgzYg3UNPjmEab_3EII9AN624PX--Bq9qHUX4M35vEY_vnzeLr8l9-uvq-XtfWKyLB8TSUxZyaICwTWpRSkkhRoMkzoHMKUkIIq8zAkRVS44Tcs0rTiFspaxRYqUX6OPJ939VMYfM3E_rzu197bX_qgGbdW_HWdb1QwHVXCeMsGjwPuzgB9-ThBG1dtgoOu0g2EKimVCUMJEmkf03RN0N0xzVDMlOUtFJmSk5IkyfgjBQ31ZhhI1J6yeJqzmhGMrjr79-zGXwT-RRmB9AnZh1A1cAO1jTh38r5xRRflczxYX0rTaK3D8N3Sfxes</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Sugihara, Koichi</creator><creator>Wakiya, Risa</creator><creator>Shimada, Hiromi</creator><creator>Kameda, Tomohiro</creator><creator>Nakashima, Shusaku</creator><creator>Kato, Mikiya</creator><creator>Miyagi, Taichi</creator><creator>Mizusaki, Mao</creator><creator>Mino, Rina</creator><creator>Nomura, Yumi</creator><creator>Inoo, Masayuki</creator><creator>Kadowaki, Norimitsu</creator><creator>Dobashi, Hiroaki</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220701</creationdate><title>Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy</title><author>Sugihara, Koichi ; Wakiya, Risa ; Shimada, Hiromi ; Kameda, Tomohiro ; Nakashima, Shusaku ; Kato, Mikiya ; Miyagi, Taichi ; Mizusaki, Mao ; Mino, Rina ; Nomura, Yumi ; Inoo, Masayuki ; Kadowaki, Norimitsu ; Dobashi, Hiroaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c667t-80cbd89de53a0f5b581efec28a7eecb80e597b7005d75314b44d31ebf880e0943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Antibody response</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Immunogenicity</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Immunoglobulins</topic><topic>immunosuppression</topic><topic>Immunosuppressive agents</topic><topic>Internal medicine</topic><topic>Janus kinase</topic><topic>Methotrexate</topic><topic>mRNA</topic><topic>mRNA vaccine</topic><topic>Original</topic><topic>Patients</topic><topic>rheumatic disease</topic><topic>Rheumatic diseases</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sugihara, Koichi</creatorcontrib><creatorcontrib>Wakiya, Risa</creatorcontrib><creatorcontrib>Shimada, Hiromi</creatorcontrib><creatorcontrib>Kameda, Tomohiro</creatorcontrib><creatorcontrib>Nakashima, Shusaku</creatorcontrib><creatorcontrib>Kato, Mikiya</creatorcontrib><creatorcontrib>Miyagi, Taichi</creatorcontrib><creatorcontrib>Mizusaki, Mao</creatorcontrib><creatorcontrib>Mino, Rina</creatorcontrib><creatorcontrib>Nomura, Yumi</creatorcontrib><creatorcontrib>Inoo, Masayuki</creatorcontrib><creatorcontrib>Kadowaki, Norimitsu</creatorcontrib><creatorcontrib>Dobashi, Hiroaki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sugihara, Koichi</au><au>Wakiya, Risa</au><au>Shimada, Hiromi</au><au>Kameda, Tomohiro</au><au>Nakashima, Shusaku</au><au>Kato, Mikiya</au><au>Miyagi, Taichi</au><au>Mizusaki, Mao</au><au>Mino, Rina</au><au>Nomura, Yumi</au><au>Inoo, Masayuki</au><au>Kadowaki, Norimitsu</au><au>Dobashi, Hiroaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>61</volume><issue>13</issue><spage>1953</spage><epage>1958</epage><pages>1953-1958</pages><artnum>9223-21</artnum><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>Objective To investigate the serum total antibody (immunoglobulin M and immunoglobulin G) titre against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain following BNT162b2 messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccination in Japanese rheumatic disease patients undergoing immunosuppressive therapy. Methods The serum antibody titre against SARS-CoV-2 spike protein was analysed in 123 outpatients with rheumatic diseases at Kagawa University Hospital and 43 healthy volunteers who had received 2 doses of the BNT162b2 mRNA vaccine with at least 14 days elapsing since the second dose. Results The antibody titre in rheumatic disease patients was significantly lower than that in healthy subjects (p<0.0001). The antibody titres of the 41 patients who received biologics or Janus kinase inhibitors and the 47 patients who received conventional immunosuppressive agents were significantly lower than those of the 35 patients who did not receive immunosuppressive agents (p<0.0001 and p<0.0001, respectively). In addition, the mean antibody titre of the 43 patients on methotrexate was significantly lower than that of the 80 patients not on methotrexate (p=0.0017). Conclusion Immunogenicity to the BNT162b2 mRNA COVID-19 vaccine in rheumatic disease patients was found to be reduced under immunosuppressive treatment. In particular, methotrexate seems to be associated with a decreased antibody response.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>35466168</pmid><doi>10.2169/internalmedicine.9223-21</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2022/07/01, Vol.61(13), pp.1953-1958 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9334253 |
| source | PubMed Central; J-STAGE; PubMed Central Open Access |
| subjects | Antibodies Antibody response Coronaviruses COVID-19 COVID-19 vaccines Immunogenicity Immunoglobulin G Immunoglobulin M Immunoglobulins immunosuppression Immunosuppressive agents Internal medicine Janus kinase Methotrexate mRNA mRNA vaccine Original Patients rheumatic disease Rheumatic diseases Severe acute respiratory syndrome coronavirus 2 Spike protein Vaccination Vaccines |
| title | Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T17%3A32%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20against%20the%20BNT162b2%20mRNA%20COVID-19%20Vaccine%20in%20Rheumatic%20Disease%20Patients%20Receiving%20Immunosuppressive%20Therapy&rft.jtitle=Internal%20Medicine&rft.au=Sugihara,%20Koichi&rft.date=2022-07-01&rft.volume=61&rft.issue=13&rft.spage=1953&rft.epage=1958&rft.pages=1953-1958&rft.artnum=9223-21&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.9223-21&rft_dat=%3Cproquest_pubme%3E2683245658%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2683245658&rft_id=info:pmid/35466168&rfr_iscdi=true |